GlaxoSmithKline plc (NYSE: NYSE:GSK) shares gained 5.65% after the pharmaceutical giant reported fourth quarter revenue that beat analyst estimates, despite earnings falling short of expectations.
GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...
Hosted on MSN29d
GSK is said to be nearing $1B deal to acquire U.S. biotech IDRxThey noted that the deal is expected to be announced before next week's JPMorgan Healthcare conference. As discussions continue, the people added that GSK (NYSE:GSK) and IDRx could opt out of the ...
Blenrep trial shows 42% lower mortality risk; peak-year sales expected over £3 billion. Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK ...
In pharmaphorum's Digital and social media themed month, Daniel Ghinn explores GSK's use of social media and the milestones it has reached to achieve its current success in this space. "There's a ...
Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a ...
The British pharma giant plans to shell out $1 billion upfront to buy the drug developer working on a lead treatment for gastrointestinal stromal tumors. As the first morning of the J.P. Morgan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback